Syph-Check Syphilis Antibody Point of Care (POC) Test
- Conditions
- Screening for Syphilis Infections
- Interventions
- Device: Syph-Check POC
- Registration Number
- NCT00732355
- Lead Sponsor
- Healthcare Providers Direct, Inc.
- Brief Summary
The study is designed to evaluate the performance of a rapid membrane test in a clinic or doctor's office setting to identify potential patients infected with syphilis and compare the results to currently licensed laboratory based tests.
- Detailed Description
The overall objectives of this study are to determine the performance characteristics of a candidate rapid point-of-care test (Syph-Check cassette format) for Treponema pallidum antibodies in serum, plasma and finger stick whole blood obtained from females and males attending sexually transmitted diseases (STD) clinics, family planning / reproductive health clinics, and physician's office; and to compare the performance of this new, rapid test to currently licensed laboratory based tests, the non-treponemal RPR and a Treponemal ELISA or TPPA test.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 400
-
Men and Women will be eligible who:
- are 18 years of age or older;
- Routine "presumed uninfected" for screening visit, or show symptomatic signs of infection or are asymptomatic but are suspected of infection, and either/or have other STD disease conditions and infections, will be identified.
- Pregnant women in the first and third trimester
- are under 18 years of age
- unwillingness to give consent
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description U Syph-Check POC presumed uninfected patients I Syph-Check POC known syphilis infected patients
- Primary Outcome Measures
Name Time Method Identify the sensitivity and specificity of the POC test versus accepted laboratory tests end of study
- Secondary Outcome Measures
Name Time Method Percent positive agreement data will include supplemental test results identified by infection categories and treatment as possible end of study
Trial Locations
- Locations (1)
Johns Hopkins University
🇺🇸Baltimore, Maryland, United States